Turkish Journal of Medical Sciences
Volume 52

Number 5

Article 8

1-1-2022

The effect of frailty on the development of acute kidney injury in
critically-ill geriatric patients with COVID-19
MURAT KÜÇÜK
BİŞAR ERGÜN
MEHMET NURİ YAKAR
ÖZER URAL ÇAKICI
ERDEM YAKA

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KÜÇÜK, MURAT; ERGÜN, BİŞAR; YAKAR, MEHMET NURİ; ÇAKICI, ÖZER URAL; YAKA, ERDEM; CÖMERT,
BİLGİN; GÖKMEN, ALİ NECATİ; and ERGAN, BEGÜM (2022) "The effect of frailty on the development of
acute kidney injury in critically-ill geriatric patients with COVID-19," Turkish Journal of Medical Sciences:
Vol. 52: No. 5, Article 8. https://doi.org/10.55730/1300-0144.5488
Available at: https://journals.tubitak.gov.tr/medical/vol52/iss5/8

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The effect of frailty on the development of acute kidney injury in critically-ill
geriatric patients with COVID-19
Authors
MURAT KÜÇÜK, BİŞAR ERGÜN, MEHMET NURİ YAKAR, ÖZER URAL ÇAKICI, ERDEM YAKA, BİLGİN
CÖMERT, ALİ NECATİ GÖKMEN, and BEGÜM ERGAN

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol52/iss5/8

Turkish Journal of Medical Sciences

Turk J Med Sci
(2022) 52: 1495-1503
© TÜBİTAK
doi:10.55730/1300-0144.5488

http://journals.tubitak.gov.tr/medical/

Research Article

The effect of frailty on the development of acute kidney injury in critically-ill geriatric
patients with COVID-19
1

1

2

3

4

5

Murat KÜÇÜK , Bişar ERGÜN , Mehmet Nuri YAKAR , Özer Ural ÇAKICI , Erdem YAKA , Bilgin CÖMERT ,
2
6,
Ali Necati GÖKMEN , Begüm ERGAN *
1
Department of Internal Medicine and Critical Care, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
2
Department of Anesthesiology and Critical Care, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
3
Department of Physiology, Faculty of Medicine, Gazi University, , Ankara, Turkey
4
Department of Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
5
Department of Internal Medicine and Critical Care, Medicana International İzmir Hospital, İzmir, Turkey
6
Department of Pulmonology and Intensive Care, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
Received: 16.09.2021

Accepted/Published Online: 09.07.2022

Final Version: 19.10.2022

Background/aim: Acute kidney injury is strongly associated with mortality in critically ill patients with coronavirus disease 2019
(COVID-19); however, age-related risk factors for acute kidney injury are not clear yet. In this study, it was aimed to evaluate the effects
of clinical factors on acute kidney injury development in an elderly COVID-19 patients.
Materials and methods: Critically ill patients (≥65years) with COVID-19 admitted to the intensive care unit were included in the study.
Primary outcome of the study was the rate of acute kidney injury, and secondary outcome was to define the effect of frailty and other
risk factors on acute kidney injury development and mortality.
Results: A total of 132 patients (median age 76 years, 68.2% male) were assessed. Patients were divided into two groups as follows: acute
kidney injury (n = 84) and nonacute kidney injury (n = 48). Frailty incidence (48.8% vs. 8.3%, p < 0.01) was higher in the acute kidney
injury group. In multivariate analysis, frailty (OR, 3.32, 95% CI, 1.67–6.56), the use of vasopressors (OR, 3.06 95% CI, 1.16–8.08), and
the increase in respiratory support therapy (OR, 2.60, 95% CI, 1.01–6.6) were determined to be independent risk factors for acute kidney
injury development. The mortality rate was found to be 97.6% in patients with acute kidney injury.
Conclusion: Frailty is a risk factor for acute kidney injury in geriatric patients with severe COVID-19. The evaluation of geriatric
patients based on a frailty scale before intensive care unit admission may improve outcomes.
Key words: Frailty, COVID-19, acute kidney injury, intensive care

1. Introduction
The World Health Organization (WHO) declared
COVID-19 a pandemic on March 11, 2020, after the
disease had been detected in 113 countries outside China
[1]. The epidemic was literally revolutionary in a regular
man’s life, as well as completely subversive to healthcare
all around the globe. A new coronavirus was identified
as the causative agent of these cases, one that had not
been detected previously in humans. The disease was
called “Coronavirus Disease 2019 (COVID-19),” and the
virus was named “Severe Acute Respiratory SyndromeCoronavirus 2 (SARS-CoV-2)” due to its close resemblance
to a previous SARS coronavirus.
Although all age groups are at risk of being infected
with COVID-19, older individuals are at higher risks of

serious disease due to aging, immunosenescence, and
underlying medical conditions. Increased cardiometabolic
diseases, decreased renal function, the use of multiple
drugs, physical inadequacies, frailty, neurological
disorders, and dementia have made the elderly a
particularly affected population during the pandemic [2].
Previous studies have shown that advanced age and the
presence of comorbidities are significantly associated with
mortality in COVID-19 patients [3,4]. Acute kidney injury
(AKI) is a common complication detected in critically ill
patients. Kidneys are more susceptible to acute damage,
especially at an advanced age [5,6]. Cheng et al. have
previously reported that serum creatinine levels at the time
of hospital admission are higher in elderly patients (mean
age, 73 years) with COVID-19 and that the presence of
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AKI is associated with poor clinical results [7]. A unique
clinical entity, named COVID-19-associated AKI, has also
been proposed to be used to name the possible direct effect
of the virus on the kidneys [8]. Structural remodeling,
vascular sclerosis, increased glomerular sclerosis, and
decreased kidney mass, which occur due to aging, are the
risk factors for acute kidney injury, in addition to coexisting
comorbidities [9]. Although the development of AKI due
to viral invasion is still not clearly understood, SARSCoV-2 nucleocapsid protein antigen has been detected
in kidney autopsy samples of COVID-19 patients with
renal dysfunction and viruses have been detected in the
parenchymal tubular epithelium and podocytes, which is
now accepted as direct evidence for viral infection [10,11].
Overall, it is well-accepted that COVID-19 patients are
more prone to develop AKI during their clinical course
[12].
Frailty is functional impairment caused by cumulative
declines across multiple organ systems. It defines an
obvious state of vulnerability, and fulfillment of three out
of five standardized clinical findings is suggested for the
definition of frailty. The criteria comprised loss of grip
strength, low energy in daily activities, slowing in waking
speed, decreased physical activity, and unintentional
weight loss [13,14]. Moreover, validated scales have come
into practice to be used in the evaluation of the patients and
foresee their outcomes [15]. Previous studies have shown
that frailty is an independent risk factor for intensive care
unit (ICU) mortality, length of stay, and rehospitalization
in critical patients [16,17]. Kader et al. have emphasized
the fact that frailty is a risk factor for AKI development
in critically ill patients [18]. However, this relationship
has not been studied in severe COVID-19 patients. The
aim of the present study was to assess the rate of AKI and
the independent effect of frailty on AKI development in
critically ill geriatric patients with COVID-19.
2. Materials and methods
2.1. Study population
Consecutive patients aged ≥65 years diagnosed with
laboratory-confirmed COVID-19 disease (diagnosis was
confirmed with a positive test for reverse transcriptionpolymerase chain reaction [RT-PCR] in any respiratory
sample or clinical, radiological, and laboratory data) and
admitted to the ICU between March 2020 and January 2021
were included in the study. Patients <65 years, those who
had been previously diagnosed with chronic kidney disease
(CKD) Stage 4–5, those who had previously received renal
replacement treatment (RRT), and those whose ICU length
of stay was <24 h were excluded. This retrospective study
was approved by the Local Ethics Committee (with date
29.03.2021 and number 2021/10-37). Informed consent
was waived because of the study design.
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2.2. Data collection
Hospital records and laboratory data for each patient were
examined, and the following data were collected: age, sex,
comorbidities, onset of symptoms, hospitalization and ICU
stay, laboratory parameters on the first day upon admission
to the ICU (arterial blood gas [PaO2: arterial partial
oxygen pressure, PaCO2: arterial partial carbon dioxide
pressure, FiO2: fraction of inspired oxygen, PO2/FiO2;
HCO3; bicarbonate, SO2; oxygen saturation], complete
blood count, C-Reactive Protein [CRP], procalcitonin,
lactate dehydrogenase [LDH], alanine aminotransferase
[ALT], aspartate aminotransferase [AST], D-dimer,
serum creatinine [sCr], total bilirubin, ferritin, and
cardiac troponin I), Acute Physiology and Chronic Health
Evaluation (APACHE) score II, the Oxygenation Index
(OI), Sequential Organ Failure Assessment (SOFA) score,
body mass index (BMI), Charlson Comorbidity Index
(CCI), complications (septic shock, cardiac injury, newonset arrhythmia, ventilator-associated pneumonia [VAP],
pneumothorax-pneumomediastinum, and acute kidney
injury), supportive treatments during hospitalization
(mechanical ventilation [MV] data, RRT, and vasoactive
drug therapy), length of ICU and hospital stays, and
mortality.
2.3. Definitions
AKI definition was determined according to the “Kidney
Disease: Improving Global Outcomes” (KDIGO)
classification system [19]. If sCr levels were within normal
limits at the time of admission, this was considered basal
sCr; if sCr changed during hospitalization and no sCr
was available before admission (within 3 months), the
lowest sCr value measured during the hospital stay was
considered basal sCr. Considering the retrospective nature
of the study and the risk of mistakes and missing data
regarding the assessment of urination at frequent intervals
included in the KDIGO criteria, only sCr was considered
as a criterion for AKI identification. The patients were
evaluated in two groups including those that developed
AKI (AKI group) and those that did not develop AKI
(non-AKI group) during ICU hospitalization.
The use of nephrotoxic drugs at any time prior to AKI
development was recorded in the non-AKI and AKI groups.
Nephrotoxic drugs were listed such as antihypertensive
and nonsteroidal antiinflammatory drugs, contrast
substance, aminoglycosides, glycopeptides, and colistin
antibiotics, which are thought to affect nephrotoxicity and
are frequently used in ICUs.
Sepsis and septic shock were defined according to the
2016 Third International Consensus on the Definition of
Sepsis and Septic Shock [20]. In addition, VAP was defined
as an increase in the amount of tracheal secretion 48 h after
intubation, darkening in color, increased purulence, and
≥105 CFU/mL reproduction in an endotracheal aspiration
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(ETA) sample [21]. If the troponin I level was above
the upper reference limit of the 99th percentile or new
abnormalities were shown upon electrocardiography and
echocardiography, this patient was considered as having
cardiac injury [22]. If the patient experienced respiratory
failure or the initial respiratory support therapy failed,
this was identified as the escalation of respiratory support
treatment. OI is calculated using the formula (FiO2 divided
by PaO2, and the division is multiplied by the mean airway
pressure) and used for its role in predicting the clinical
outcomes in respiratory failure [23].
The frailty degree was evaluated with the Frail Scale
[24]. This scale evaluates fatigue, muscle resistance,
aerobic capacity, disease load, and weight loss. Fatigue
is mostly evaluated by asking if patients feel tired, and
muscle resistance is measured with a report showing
the capacity of patients to climb one floor of stairs. The
aerobic reserve is identified with independent walking
capacity; disease load is defined as having five of a total
of eleven diseases (hypertension, diabetes mellitus, cancer
[basal-cell carcinoma or equivalent excluded], chronic
obstructive pulmonary disease, coronary artery disease
or myocardial infarction, congestive heart failure, asthma,
arthritis, and cerebrovascular disease chronic kidney
disease), and finally, weight loss was defined as having had
a decrease of 5% or more in weight in the last 6 months.

Patients were classified as nonfrail for a total score of
0, prefrail for 1–2 points, and frail for ≥3 scores. Frail scale
score was calculated using the information from patients
or patients’ relatives.
2.4. Statistical analysis
All continuous variables were presented as mean ±
standard deviation [SDs] or median (inter-quartile ranges
[IQRs]), and categorical variables were presented as
numbers and percentages (%). For all variables, descriptive
statistics were calculated with Student’s t-test, MannWhitney U-Test, χ2, or Fisher’s Exact Test. Multivariate
logistic regression analysis was performed, using the Enter
Method, to investigate the risk factors in AKI development.
A p-value of <0.05 was considered statistically significant.
The Statistical Package for the Social Sciences (SPSS)
Version 26.0 (IBM) was used for all analyses.
3. Results
3.1. Patient characteristics
A total of 306 critically ill patients who had COVID-19
were admitted to the ICU. Of these, 175 were over the
age of 65. Forty-three patients were excluded due to the
exclusion criteria, and 132 patients were included in the
study (Figure). Acute kidney injury was detected in 84
(63.6%) of them.

Figure. Flowchart of the study.
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The median age of the AKI group was similar to that of
the non-AKI Group (76 [70–83] vs. 72 [69–80], p = 0.09).
APACHE II score was higher in the AKI group than in the
non-AKI group (23 [15–28] vs. 19 [11–23], respectively,
p = 0.02). Similarly, the SOFA score, in terms of intensive
care admission, was higher in the AKI group than in the
non-AKI group (6 [5–7], vs. 4 [3–5], p = 0.02). The number
of frail patients was significantly higher in the AKI group
than in the non-AKI group (48.8% vs. 8.3%, p ≤ 0.01).
Conversely, nonfrail patients were significantly higher in

the non-AKI group than in the AKI group (43.8% vs. 19%,
p =< 0.01. All clinical data of the cohort is given in Table 1.
3.2. Laboratory findings and AKI classification
LDH (596 [492–768] U/L vs. 534 [370–669] U/L, p = 0.02)
and D-dimer (1.95 [1.30–4.5] mg/mL vs. 1.35 [0.8–3.2]
mg/ml, p = 0.03) were higher in the AKI group than in the
non-AKI group.
Among the AKI developing patients, eleven (13.1%)
had Stage 1, 16 (19%) had Stage 2 and 57 (67.9%) had Stage
3 AKI. Laboratory data of the cohort is given in Table 2.

Table 1. Clinical characteristics and comorbidities of older patients with COVID-19.
Characteristic

All Patients (n = 132) Non-AKI Patients (n = 48)

AKI Patients (n = 84)

p- value

Age (range)

76 (76–83)

72 (69–80)

77 (70–83)

0.09

Male (%)

90 (68.2)

28 (58.3)

62 (73.8)

Female (%)

42 (31.8)

20 (41.7)

22 (26.2)

Time from symptom onset to ICU
admission, days (range)

7 (3–10)

7 (4-9)

7 (3–10)

0.09

Length of hospital stay before ICU
admission, days (range)

2 (1–6)

2 (1-6)

2 (1–5)

0.46

SOFA Score1 (range)

5 (4–7)

4 (3-5)

6 (5-7)

0.02

BMI kg/m2 (range)

26 (22–28)

26 (22-27)

26 (22–29)

0.56

CCI (range)

5 (4–7)

5 (3-7)

6 (4–7)

0.06

Nonfrail (%)

37 (28)

21 (43.8)

16 (19)

<0.01

Prefrail (%)

50 (37.9)

23 (47.9)

27 (32.1)

0.09

Frail (%)

45 (34.1)

4 (8.3)

41 (48.8)

<0.01

Hypertension (%)

109 (82.6)

39 (81.2)

70 (83.3)

0.81

Diabetes mellitus (%)

48 (36.4)

17 (35.4)

31 (36.9)

1.00

Coronary artery disease (%)

39 (29.5)

11 (22.9)

28 (33.3)

0.23

Congestive heart failure (%)

Sex
0.06

Frailty Scale

Chronic medical illness

22 (16.7)

6 (12.5)

16 (19)

0.46

Chronic kidney disease (Stage 1–3) (%) 19 (14.4)

5 (10.4)

14 (16.7)

0.44

Dementia (%)

19 (14.4)

6 (12.5)

13 (15.5)

0.79

Obstructive pulmonary disease (%)

17 (12.9)

7 (14.5)

10 (11.9)

0.06

Malignancy (%)

14 (10.6)

3 (6.3)

11 (13.1)

0.25

Cerebrovascular disease (%)

11 (8.3)

1 (2.1)

10 (11.9)

0.05

Chronic atrial fibrillation (%)

10 (7.6)

4 (8.3)

6 (7.1)

1.00

Hyperlipidemia (%)

9 (6.8)

2 (4.2)

7 (8.3)

0.48

Parkinson’s disease (%)

6 (4.5)

2 (4)

4 (4)

0.66

2

All values are expressed as numbers (percentages) or median (interquartile range).
Abbreviations: AKI: Acute kidney injury; APACHE: Acute physiology and chronic health evaluation; BMI: Body mass index. CCI:
Charlson Comorbidity Index. SOFA: Sequential Organ Failure Assessment score
1
On the day of intensive care unit admission
2
Includes hematological and solid organ malignancies
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Table 2. Laboratory findings and KDIGO AKI staging of older patients with COVID-19.

Leukocyte 10 /UL (range)

11.4 (8–14.8)

Non-AKI Patients (n =
48)
10.6 (6.4–9.7)

Lymphocytes 10 /UL (range)

0.5 (0.4–0.9)

0.5 (0.4–0.8)

0.5 (0.3–1)

0.94

Hemoglobin gr/dL (range)

12.4 (11.1–13.6)

12.05 (11–13.4)

12.75 (11.1–13.8)

0.21

CRP mg/L (range)

161 (92.2–228)

141 (88–210)

174 (110–241)

0.20

Procalcitonin ng/mL (range)

0.33 (0.15–1.06)

0.24 (0.08–1.07)

0.36 (0.18–1.06)

0.09

LDH U/L (range)

564 (357–827)

534 (370–669)

596 (492–768)

0.02

Ferritin ng/mL (range)

523 (375–827)

481 (210–824)

539 (294–846)

0.12

Troponin ng/mL (range)

30 (11–205)

24 (8–93)

36 (15.6–261)

0.38

ALT U/L (range)

32 (19–54)

32 (22–65)

33 (19–47)

0.40

AST U/L (range)

51 (35–78)

45 (32–88)

51 (37.5–75)

0.60

Total bilirubin mg/dL (range)

0.92 (0.63–1.14)

0.75 (0.60–1.12)

0.95 (0.65–1.18)

0.17

D-dimer µg/mL (range)

1.70 (1.1–3.97)

1.35 (0.8–3.2)

1.95 (1.30–4.5)

0.03

Baseline sCr mg/dL (range)

0.89 (0.7–1.1)

0.87 (0.69–0.92)

0.92 (0.76–1.10)

0.09

sCr on ICU admission mg/dL (range)

1.02 (0.85–1.39)

1.01(0.80–1.19)

1.10 (0.89–1.31)

0.11

PaO2/FiO2 ratio (range)

117 (96–154)

127 (101–163)

108 (93–151)

0.13

Grade 1 (%)

11 (8.3)

-

11 (13.1)

Grade 2 (%)

16 (12.1)

-

16 (19)

Grade 3 (%)

57 (43.2)

-

57 (67.9)

pH (range)

7.41 (7.32–7.47)

7.43 (7.33–7.47)

7.39 (7.29–7.4)

0.38

PaO2 mmHg (range)

65 (55–81)

69 (57–84)

61 (52–76)

0.07

PaCO2 mmHg (range)

35 (31–44)

35 (31–45)

35 (30–44)

0.45

FiO2 (range)

0.6 (0.5–0.6)

0.6 (0.5–0.6)

0.6 (0.5–0.6)

0.91

SaO2 % (range)

92 (88–95)

93 (90–96)

91 (86–94)

0.06

HCO3 mmol/L (range)

23 (20–25)

24 (20–26)

23 (20–25)

0.07

Lactate mmol/L (range)

1.95 (1.4–2.95)

1.85 (1.2–3.2)

2.05 (1.42–2.8)

0.35

Variables

All Patients (n = 132)
3

3

AKI Patients (n = 84)

p- value

11.4 (8.2–14.6)

0.74

KDIGO AKI staging
NA

Arterial blood gas analysis

AKI: Acute kidney injury; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PaO2: Arterial partial oxygen pressure;
PaCO2: Arterial partial carbon dioxide pressure; CRP: C-Reactive protein; FiO2: Fraction of inspired oxygen; HCO3: Bicarbonate;
KDIGO: Kidney disease: improving global outcomes; LDH: Lactate dehydrogenase; SO2: Oxygen saturation; sCr: Serum creatinine

3.3. Characteristics for ICU stay
The incidence of VAP (63.1%, vs. 31.3%, p < 0.01) and
septic shock (91.7% vs. 41.7, p < 0.01) were higher in the
AKI group than in the non-AKI group during ICU stay.
The increase in respiratory support treatment during
ICU hospitalization (59.5% vs. 33.3%, p < 0.01) and the
development of vasopressor requirements (83.3% vs.
45.8%, p < 0.01) were significantly higher in the AKI group
than in the non-AKI group.
In all patients, ICU mortality was 75% (99/132),
and hospital mortality was 76.5% (101/132). In the AKI
group, ICU and hospital mortality were significantly

higher (97.6% vs. 35.4%, p < 0.01; 97.6% vs. 39.6%, p
< 0.01, respectively) than in the non-AKI group. It was
also found that 38.2% of the patients in the group that
developed AKI received RRT and all died. Additionally,
ICU survival was detected in two patients who developed
Stage 1 AKI. Among all patients, ICU and hospital
mortality was 97.7% (44/45) in frail patients and 48.6%
(18/37) in nonfrail patients. In prefrail patients, ICU
mortality was 74% (37/50), and hospital mortality was
78% (39/50).
Clinical data involving the course during the ICU stay
is given in Table 3.
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Table 3. Complications, treatments, and outcomes of older patients with COVID-19.
Variables

All Patients (n = 132) Non-AKI Patients (n = 48) AKI Patients (n = 84) p- value

Complications
Septic Shock (%)

97 (73.5)

20 (41.7)

77 (91.7)

<0.01

VAP (%)

68 (51.5)

15 (31.3)

53 (63.1)

<0.01

Arrhythmia (%)

12 (9)

4 (8.3)

8 (9.5)

0.57

Cardiac injury (%)

36 (27.3)

10 (20.8)

26 (31)

0.23

Pneumothorax/pneumomediastinum (%)

19 (14.4)

7 (14.5)

12 (14.2)

0.12

IMV (%)

51 (38.6)

17 (35.4)

34 (40.5)

0.58

NIMV (%)

9 (6.9)

3 (6.3)

6 (7.1)

1.00

HFNO (%)

39 (29.5)

16 (33.3)

23 (27.4)

0.55

COT (%)

33 (25)

12 (25)

21 (25)

1.00

Escalation in respiratory support Treatment * (%) 66 (50)

16 (33.3)

50 (59.5)

<0.01

RRT (%)

38 (28.8)

0 (0.0)

38 (45.2)

Vasopressors1 (%)

92 (69.6)

22 (45.8)

70 (83.3)

<0.01

Antivirals (%)

129 (97.7)

48 (100)

81 (96.4)

0.55

IV Corticosteroid (%)

104 (78.7)

40 (83)

64 (76.2)

0.38

Pulse corticosteroid (%)

54 (40)

19 (39)

35 (41)

0.85

LMWH (%)

129 (97.7)

46 (95.8)

83 (98.8)

0.29

Nephrotoxic agent use** (%)

38 (28.7)

9 (18.7)

29 (34.5)

0.07

Duration of IMV, days (range)

9 (4–14)

8 (4–15)

9 (4-14)

0.84

Length of hospital stay, days (range)

16 (11–21)

16(14–21)

15 (10–20)

0.08

Length of ICU stay days (range)

10 (6–16)

8 (5–17)

11 (6–16)

0.18

Hospital mortality (%)

101 (76.5)

19 (39.6)

82 (97.6)

<0.01

ICU mortality (%)

99 (75)

17 (35.4)

82(97.6)

<0.01

Treatments
Initial respiratory support treatment

2

3

Outcomes

All values are expressed as numbers (percentages) or median (interquartile range).
Notes: 1 Norepinephrine > 0.15 Μg/Kg/min
2
Iv Corticosteroid*: intravenous 0.5–1 mg/kg/day
3
Pulse Corticosteroid*:> 250 mg/day
*If the patient is altered in respiratory failure or has failed from HFNO
**Drugs with nephrotoxicity: mainly included aminoglycosides, glycopeptides, and colistin
Abbreviations: COT: Conventional oxygen therapy; HFNOT: High flow nasal oxygen therapy; ICU: Intensive care unit; IMV: Invasive
mechanical ventilation; IV: Intravenous; NIMV: Noninvasive mechanical ventilation; RRT: Renal replacement therapy; VAP: Ventilatorassociated pneumonia

3.4. Multivariate model for AKI development
The variables included in the regression model were
APACHE II score, CCI, frailty score, vasopressor
requirement, the increase in respiratory support, and
nephrotoxic drug use. Frail patients (OR 3.32; 95% CI,
1.67–6.56, p < 0.001), vasopressor requirement (OR

1500

3.06; 95% CI, 1.16–8.08, p = 0.02), and the increase
in respiratory support (OR 2.60; 95% CI, 1.01–6.6, p
= 0.04) were identified as independent risk factors for
AKI development in elderly patients with COVID-19
disease. The results of the multivariate analysis are given
in Table 4.
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Table 4. Risk factors associated with acute kidney injury in the multivariate regression analysis
among patients with COVID-19. (95% CI: 95% confident interval).
OR (95% CI)

p-value

Frailty

3.32 (1.67–6.56)

<0.001

Use of vasopressors

3.06 (1.16–8.08)

0.02

Escalation in respiratory support

2.60 (1.01–6.6)

0.04

Charlson comorbidity index

1.00 (0.81–1.23)

0.98

APACHE II score

1.02 (0.96–1.09)

0.36

Nephrotoxic agent use

1.5 (0.56–4.03)

0.41

*

Abbreviations: APACHE; Acute Physiology and Chronic Health Evaluation
*
Multivariate analysis carried out grouping the fraile vs. not fraile (including
prefrail and nonfrail) patients of the cohort.

4. Discussion
We evaluated the factors that affected AKI development
and ICU mortality in elderly patients with COVID-19,
and three important results were found. First, the AKI
rate was 63.6% in geriatric patients with severe COVID-19
disease. Second, the mortality rate was significantly
higher in patients with AKI, while AKI is a relatively
common problem in patients >65 years of age with severe
COVID-19. Third, frailty alone increased the risk of AKI
development three-fold.
Although the incidence of AKI in COVID-19 disease
varies between 37% and 46%, it has been reported to
increase up to 68% in patients admitted to the ICU [25,26].
Current evidence suggests that the COVID-19 course is
complicated by a high risk of AKI [27]. The incidence of
AKI in critically ill patients with COVID-19 disease over
65 years of age was 63.6% in our study, and it was found
that AKI development was associated with high mortality
in the geriatric patient group (97.6%). However, mortality
rates have been found differently in patients with AKI in
a study conducted by Alessandri et al. in that AKI has
been found to have developed in 57% of critical patients
with COVID-19 disease, and age has been identified
as a significant risk factor for AKI development. In the
same study, the mortality rate has been found as 69% in
the entire patient group, while it has been determined as
90% in patients with Stage-3 AKI [28]. In another study
conducted by Piñeiro et al., the rate of AKI development
in the ICU has been found as 22% and the mortality rate
was 52% in the patient group with a median age of 72 years
[29].
The presence of frailty upon ICU hospitalization
in critically elderly patients with COVID-19 disease
was identified as an independent risk factor for AKI
development in the present study. Frail patients were
found to have 100% mortality in the AKI-developing

group. Previous studies have reported that frailty is
independently associated with ICU mortality (16). In a
study in which ICU mortality is 69%, it has been shown
that there is a correlation between SOFA and APACHE II
scores and frailty, and the survival rates of frail patients are
lower at 1 and 6 months after ICU discharge [17].
The scoring systems typically used to determine the
prognosis of patients in ICUs are APACHE II and SOFA
[30]. However, no specific tests are available for critical
elderly patients with which clinical outcomes are predicted.
It must be kept in mind that frailty can be an important
factor in the evaluation of these patients, especially
considering that mortality increases with frailty at
significant levels in this age group. We believe that it would
be very valuable to assess patients for frailty, in addition
to the scores we are currently using. Moreover, it would
also be helpful for the decision-making process regarding
life-supporting aggressive treatments or palliative care for
these patients. While examining the frailty status, we used
the Frail Scale considering its evidence-supported role to
indicate mortality [31].
Studies examining the effects on AKI development,
risk factors and mortality in elderly critical COVID-19
patients are inadequate in the present time. In the study
conducted by Li et al., AKI has developed in 59% of elderly
critical COVID-19 patients, and mortality has been found
as 97.2% [32]. In the same study, invasive mechanical
ventilation (IMV) and vasopressor need, and septic shock
have been found higher in the group that developed AKI.
Furthermore, LDH and D-dimer levels and basal sCr on
hospitalization are higher in the group that developed AKI.
Similarly, the need for vasopressors was an independent
risk factor for AKI development (OR 3.06) in this study.
In addition, elevated LDH and D-dimer levels, which
are the biomarkers associated with disease severity, were
higher in the group that developed AKI at statistically
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significant levels. In our study, although no significant
differences were detected in blood gas values in the ICU
hospitalization of patients, OI was lower in the AKI group;
however, no significant differences were detected between
initial respiratory support treatments in both groups.
However, it was determined in the follow-ups that the
increase in respiratory support was significantly higher
in the AKI group and was an independent risk factor for
AKI. When considered from this point of view, it may be
that permissive hypoxia has increased effects on sensitive
kidneys, and late intubation may increase the risk of AKI
development. Although basal and ICU-hospitalization
SCr values were higher in the AKI group, no statistically
significant differences were detected in our study. However,
given that patients with Stage 1–3 chronic kidney disease
were more common in the AKI group (16.7% vs. 10.4%),
this group may be at a higher risk of AKI development. The
incidence of VAP and septic shock was significantly higher
in the AKI group. Although the difference between the
groups was not statistically significant, the high number of
MV days and immunosuppressive treatments in the AKI
group may have caused increased VAP incidence.
Our study has certain limitations. First, the study was
conducted in the ICU of a single medical center; therefore,
the results cannot be generalized. Another limitation was
information bias due to the retrospective nature of the
study. The frailty status of some patients who could not
communicate was assessed according to the data provided

by relatives. The present study also has certain strengths.
Although AKI and mortality data for severe COVID-19
are present in the literature, specific data for the geriatric
population remain limited. Moreover, to the best of our
knowledge, this is the first study to assess a new risk factor
for AKI development, the frailty score, in geriatric patients
with severe COVID-19.
In conclusion, this study examined frailty and other risk
factors that affect AKI development in elderly COVID-19
patients admitted to the ICU due to critical disease and
found that frailty was an independent risk factor for AKI
development. Frailty scale scores must be examined in all
elderly patients, particularly in those admitted to ICUs
with COVID-19, and further studies must be conducted
regarding the use of frailty as a prognostic marker.
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